poster

Incremental Burden of Relapse in Patients with Major Depressive Disorder

Objective: Assessment of incremental clinical and economic burdens of relapse in patients with major depressive disorder (MDD).

11/22/2019

The Efficacy of Lumateperone 42 mg in the Treatment of Schizophrenia: A Pooled Analysis of Randomized Controlled Trials

Introduction: Lumateperone (lumateperone tosylate, ITI-007) is in late-phase clinical development for schizophrenia. Lumateperone has a unique mechanism of action that simultaneously modu...

11/22/2019

The Association Between COMT Genotype and Bupropion Treatment Response in Outpatients With Major Depressive Disorder

Background: Studies examining treatment responses to antidepressants based on genotype have produced inconsistent findings. Although catechol-O-methyltransferase (COMT) metabolizes catech...

11/22/2019

A Comparison of Barriers and Drivers Between Prescribing and Non-Prescribing Psychiatric Care Providers Regarding Use of Digital Medication Adherence Platforms

Background: Tracking medication adherence through an ingestible event monitoring (IEM) sensor could benefit seriously mentally ill patients (SMI). Psychiatric providers may be reluctant t...

11/22/2019

Journey of the Veteran Health Administration Population With Recent Schizophrenia Diagnosis: A Real-World Analysis of Treatment Patterns and Healthcare Burden

Background: Schizophrenia is a chronic mental disorder that affects ~0.3-0.7% of the population worldwide and poses a significant economic and societal burden. Objectives: To describe tr...

11/22/2019

The Cost of Improving Treatment Choices: Cost and Benefit of a Digital Medicine System that Collects and Reports Objective Medication Adherence

Background: Medication adherence is critical for relapse prevention among SMI patients. In the absence of objectively collected adherence data (OCAD), managing medications is difficult. A...

11/22/2019

Long-Term Treatment With Deutetrabenazine Is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From an Open-Label Extension Study

BACKGROUND: In the 12-week ARM-TD and AIM-TD studies of patients with tardive dyskinesia (TD), the percentage of patients achieving ≥50% and ≥70% responses (i.e. reductions from baseline ...

11/22/2019

Effects of Aripiprazole Once-Monthly and Paliperidone Palmitate Once Monthly in Patients With Schizophrenia and Concomitant Substance Use: A Post-hoc Analysis of QUALIFY, a Head-to-Head Study

Background: Post-hoc analyses of the QUALIFY study (1), comparing effects of aripiprazole once-monthly (AOM 400) and paliperidone palmitate once-monthly (PP1M) treatment in patients with ...

11/22/2019

Efficacy and Safety of SEP-363856, a Novel Psychotropic Agent with a Non-D2 Mechanism of Action, in the Treatment of Schizophrenia: A 4-Week, Randomized, Placebo-Controlled Trial

Background: SEP-363856 is a novel trace amine associated receptor-1 (TAAR1)/5-HT1A agonist with no dopamine-D2/5-HT2A antagonist activity which has shown efficacy in animal models of psyc...

11/22/2019

Assessment of Health-Related Quality of Life and Health Status in Patients With Treatment Resistant Depression Treated With Esketamine Nasal Spray Plus Oral Antidepressant Using European Quality of Life Group-5-Dimension-5-Level

Objective: To assess health-related quality of life (HRQoL) and health status of patients with treatment resistant depression (TRD), treated with esketamine nasal spray+oral antidepressan...

11/22/2019

Tracks

Schizophrenia Insights

Major Depressive Disorder

General Psychiatry

ADHD

MDD Insights

About

Celebrating 35 years of empowering the highest standard in mental healthcare, Psych Congress serves as a unique, integrated forum to connect members of the entire mental health team—bringing together psychiatrists, nurse practitioners, physician assistants, psychologists, primary care physicians, and other mental health professionals for 4 days of practical education to improve patient care.

December 9 ⁠–⁠ December 11

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

May 28 ⁠–⁠ May 31

See Full Calendar

poster

Tracks

About

Specialties

Events

Year Round Education

HMP Global Products